InflaRx N.V. (IFRX)
NASDAQ: IFRX
· Real-Time Price · USD
1.85
0.15 (8.82%)
At close: May 01, 2025, 3:59 PM
1.78
-3.78%
After-hours: May 01, 2025, 05:45 PM EDT
8.82% (1D)
| Bid | 1.41 |
| Market Cap | 124.2M |
| Revenue (ttm) | 166K |
| Net Income (ttm) | -46.12M |
| EPS (ttm) | -0.88 |
| PE Ratio (ttm) | -2.1 |
| Forward PE | -2.69 |
| Analyst | Buy |
| Ask | 1.95 |
| Volume | 380,214 |
| Avg. Volume (20D) | 418,998 |
| Open | 1.73 |
| Previous Close | 1.70 |
| Day's Range | 1.70 - 1.86 |
| 52-Week Range | 0.82 - 2.81 |
| Beta | 2.22 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III c...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 7, 2017
Employees 74
Stock Exchange NASDAQ
Ticker Symbol IFRX
Website https://www.inflarx.de
Analyst Forecast
According to 3 analyst ratings, the average rating for IFRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 440.54% from the latest price.
Stock ForecastsNext Earnings Release
InflaRx N.V. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 days ago
+18.85%
InflaRx shares are trading higher after Cantor Fit...
Unlock content with
Pro Subscription
2 months ago
-25.93%
InflaRx shares are trading lower after the company announced the pricing of a $30 million public offering of 8.25 million shares at $2.00 each and pre-funded warrants.
